Cargando…

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline

BACKGROUND: The effects on cardiovascular disease (CVD) by treatment recommendations on prevention of atherosclerotic CVD remain to be evaluated. The objectives were to assess treatment gap for low density lipoprotein cholesterol (LDL-C) according to guidelines, potential impact on CVD outcomes, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Journath, Gunilla, Hambraeus, Kristina, Hagström, Emil, Pettersson, Billie, Löthgren, Mickael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559790/ https://www.ncbi.nlm.nih.gov/pubmed/28814290 http://dx.doi.org/10.1186/s12872-017-0659-2

Ejemplares similares

Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes
por: Walz, Lotta, et al.
Publicado: (2014)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
por: Gandra, Shravanthi R., et al.
Publicado: (2016)

Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year
por: Tran, Josephine N., et al.
Publicado: (2016)

Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006–2019: a registry-based cohort study
por: Leosdottir, Margret, et al.
Publicado: (2023)

Socioeconomic Disparities and Mediators for Recurrent Atherosclerotic Cardiovascular Disease Events After a First Myocardial Infarction
por: Ohm, Joel, et al.
Publicado: (2023)

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
por: Faridi, Kamil F., et al.
Publicado: (2023)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group
por: Journath, Gunilla, et al.
Publicado: (2020)

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
por: Shaya, Fadia Tohme, et al.
Publicado: (2019)

Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
por: Li, Sha, et al.
Publicado: (2022)

Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study
por: Hadaegh, Farzad, et al.
Publicado: (2021)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)
por: Pettersson, Billie, et al.
Publicado: (2010)

Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data
por: Lindh, Maria, et al.
Publicado: (2019)

Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events
por: Brown, Rosemary Elisabeth, et al.
Publicado: (2020)

New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China()
por: Hu, Da-Yi
Publicado: (2016)

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
por: Kinoshita, Makoto, et al.
Publicado: (2018)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
por: Cannon, Christopher P., et al.
Publicado: (2021)

Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
por: Citarella, Anna, et al.
Publicado: (2022)

Inflammation in atherosclerotic cardiovascular disease
por: Shah, Prediman K., et al.
Publicado: (2019)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm
por: Hageman, Steven H J, et al.
Publicado: (2022)

Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science
por: German, Charles Amir, et al.
Publicado: (2020)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Atherosclerotic Cardiovascular Disease Beginning in Childhood
por: Hong, Young Mi
Publicado: (2010)

The gut microbiome in atherosclerotic cardiovascular disease
por: Jie, Zhuye, et al.
Publicado: (2017)

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease
por: Power, Thomas P, et al.
Publicado: (2018)

Acute and chronic impact of cardiovascular events on health state utilities
por: Matza, Louis S, et al.
Publicado: (2015)

Evaluating algorithmic fairness in the presence of clinical guidelines: the case of atherosclerotic cardiovascular disease risk estimation
por: Foryciarz, Agata, et al.
Publicado: (2022)

Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
por: Nurmohamed, Nick S, et al.
Publicado: (2023)

Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden
por: Journath, Gunilla, et al.
Publicado: (2015)

Lipid Management in a Japanese Community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012
por: Tada, Hayato, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sd2hcq4ru8o5dtvrtu7q3dgkb2